非糖尿病供心移植至糖尿病受者后心脏脂质蓄积研究
DMCM-AHEAD前瞻性研究纳入158例首次心脏移植受者(82例非糖尿病,76例糖尿病,其中46%使用二甲双胍),通过系列心内膜活检评估心肌细胞脂质蓄积。结果显示糖尿病受者早期即出现进行性心肌细胞脂质蓄积(p=0.019),二甲双胍使用与脂质蓄积减少独立相关(HR 6.597,95%CI 2.516-17.296,p<0.001)。
要点
- 糖尿病受者心脏移植后早期出现进行性心肌细胞脂质蓄积
- 二甲双胍使用与减少脂质蓄积独立相关
- 脂毒性因子在糖尿病受者中增加,二甲双胍组减少
核心结论
- 人糖尿病心肌病早期发病始于心脏移植后糖尿病受者的心肌细胞脂质蓄积。
- 二甲双胍使用与减少脂质蓄积独立相关,独立于免疫抑制治疗。
研究设计与样本
- DMCM-AHEAD前瞻性ongoing研究(NCT03546062),评估158例首次心脏移植受者(82例非糖尿病,76例糖尿病,其中35例[46%]使用二甲双胍)。
- 受者接受临床标准评估(代谢状态、超声心动图、冠状动脉CT血管造影和心内膜活检),活检评估免疫反应、油红O染色、神经酰胺和甘油三酯水平。
主要发现
- 糖尿病受者出现显著早期进行性心肌细胞脂质蓄积,非糖尿病受者无此现象(p=0.019)。
- 二甲双胍亚组与未使用药物的糖尿病受者相比,脂质蓄积减少(HR 6.597;95%CI 2.516-17.296;p<0.001),免疫抑制治疗组间相似。
- 脂毒性因子在糖尿病受者中较非糖尿病受者增加,二甲双胍使用与更少脂毒性因子相关。
临床怎么用
- 对于糖尿病心脏移植受者,应关注心肌脂质蓄积作为糖尿病心肌病早期标志。
- 二甲双胍可能作为减少心肌脂质蓄积的潜在治疗选择,但需进一步随机研究验证。
局限性
- 二甲双胍 subgroup 为非随机化设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early pathogenesis of diabetic cardiomyopathy (DMCM) may involve lipotoxicity of cardiomyocytes in the context of hyperglycemia. There are many preclinical studies of DMCM pathogenesis, but the human evidence is still poorly understood. OBJECTIVES: By using a nondiabetic mellitus (non-DM) heart transplanted (HTX) in diabetes mellitus (DM) recipients, this study conducted a serial study of human heart transplant recipients evaluating cardiac effects of diabetic milieu (hyperglycemia and insulin resistance) on lipotoxic-mediated injury. We evaluated cardiomyocyte morpho-pathology by seriated biopsies of healthy implanted hearts in DM recipients during 12-month follow-up from HTX. Because metformin reduces ectopic lipid accumulation, we evaluated the effects of the drug in a nonrandomized subgroup. METHODS: The DMCM-AHEAD (Diabetes and Lipid Accumulation and Heart Transplant) prospective ongoing study (NCT03546062) evaluated 158 first HTX recipients (82 non-DM, 76 DM of whom 35 [46%] were receiving metformin). HTX recipients were undergoing clinical standard evaluation (metabolic status, echocardiography, coronary computed tomography angiography, and endomyocardial biopsies). Biopsies evaluated immune response, Oil Red-O staining, ceramide, and triacylglycerol levels. Lipotoxic factors and insulin resistance were evaluated by reverse transcriptase-polymerase chain reaction. RESULTS: There was a significant early and progressive cardiomyocyte lipid accumulation in DM but not in non-DM recipients (p = 0.019). In the subgroup receiving metformin, independently from immunosuppressive therapy that was similar among groups, lipid accumulation was reduced in comparison with DM recipients not receiving the drug (hazard ratio: 6.597; 95% confidence interval: 2.516 to 17.296; p < 0.001). Accordingly, lipotoxic factors were increased in DM versus non-DM recipients, and, relevantly, metformin use was associated with fewer lipotoxic factors. CONCLUSIONS: Early pathogenesis of human DMCM started with cardiomyocyte lipid accumulation following HTX in DM recipients. Metformin use was associated with reduced lipid accumulation independently of immunosuppressive therapy. This may constitute a novel target for therapy of DMCM.
引用
- Marfella R, Amarelli C, Cacciatore F, et al. Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients. J Am Coll Cardiol. 2020. PMID: 32192650. doi:10.1016/j.jacc.2020.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。